Reports Q4 revenue $177.8M, consensus $169.46M. "Myriad Genetics ended 2022 with a strong fourth quarter. Our market-leading hereditary cancer test, MyRisk, achieved double-digit year-over-year growth in the quarter – a reflection of our team’s hard work and the execution of our strategic growth plan," said CEO Paul Diaz. "We believe 2023 will be an exciting year as we continue to invest in our Labs of the Future strategy and enabling technologies to enhance our ability to better serve our patients and provider partners. We plan to introduce a number of new products in the second half of 2023, including Precise Liquid and FirstGene. And we are on-track to introduce Precise MRD to our pharma partners for research use. We remain confident in our ability to achieve our goal of 10%+ annual growth by 2024 based on the progress we made in 2022 and the strong start to the year we are seeing through February. As we look to 2024 and beyond, we are excited about our robust product pipeline and a capital structure that enables Myriad Genetics to invest in future innovation and growth."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
- Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
- Myriad Genetics to Participate in Upcoming Healthcare Conferences
- Myriad Genetics highlights 2022 research findings
- Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing